What sector does Gland Pharma Limited belong to?

Gland Pharma Limited operates in the Healthcare sector, specifically the Pharmaceuticals industry, and is listed on the NSE.

What is the current share price of GLAND?

As of the latest available quote, GLAND traded at ₹2,922.30. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of GLAND?

Gland Pharma Limited has a price-to-earnings (P/E) ratio of about 42.74. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of GLAND?

The market capitalisation of Gland Pharma Limited is approximately ₹48,208 Cr.

Is Gland Pharma Limited profitable?

For its latest reported financial year, Gland Pharma Limited recorded a net profit margin of about 15.97%.

Does GLAND pay a dividend?

Gland Pharma Limited currently has a dividend yield of about 0.68%.

What is the return on equity (ROE) of GLAND?

Gland Pharma Limited has a return on equity (ROE) of about 10.70%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of GLAND?

Over the past 52 weeks, GLAND has traded between a low of ₹1,573.60 and a high of ₹3,042.00.

Gland Pharma Limited

GLAND NSE Healthcare Pharmaceuticals

Nifty 500 Smallcap 50 Smallcap 100 Smallcap 250

₹2,922.30

-0.83%

Delayed · cached 15 min

Fair value analysis

GLAND

Gland Pharma Limited

₹2,946.90

Close used for this calculation

₹1,337.30Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

48/100

Profitability17/25

Returns6/25

Balance Sheet21/25

Efficiency4/25

Growth3/25

Average

Quality radar

Consensus fair value

₹1,337.30

Above FV

▼ -54.6% against the close used

Model range ₹598.56 – ₹2,225.90

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₹598.56Fair value₹1,337.30Bull₹2,225.90

FairClose

52-week traded range

52W low ₹1,596.8052W high ₹3,026.20

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

Gland Pharma Limited closed at ₹2,946.90, 120.4% above the consensus fair value of ₹1,337.30 drawn from 9 valuation models.

Financial DNA score 48/100 — Average. P/E of 42.1x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

₹652.78

-77.8%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=9%, r=10%, tg=3%, n=10yr

Graham Number

₹995.69

-66.2%

√(22.5 × EPS × BVPS)

EPS=62.35, BVPS=706.69 · outside Graham range (P/E 42.1, P/B 4.2) — asset-light, treat as a rough floor

Graham Formula

₹1,603.73

-45.6%

EPS × (8.5 + 2g) × 6.5 ÷ FD_Rate

g=9.6%, FD=7%

P/E Fair Value

₹2,225.90

-24.5%

EPS × 35.7x (sector P/E)

EPS=62.35, Sector P/E=35.7x

Peter Lynch (PEG)

₹598.56

-79.7%

EPS × Growth% (PEG = 1 is fair)

EPS=62.35, g=9.6%

EV/EBITDA

₹1,840.91

-37.5%

(EBITDA × 14.8x − Net Debt) ÷ Shares

EBITDA=20.54B

Book Value (P/B)

₹830.36

-71.8%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=706.69, ROE=10.7%, g=6%, r=10%

Reverse DCF

₹2,946.90

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 18.8% | Historical: 9.6%

Margin of Safety

₹1,027.14

-65.1%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=1369.53, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer